The Southern Oregon Potter’s Association is celebrating the 50th Clayfolk Fall Pottery Show & Sale at the Medford Armory. The ...

Every function in a cell is associated with a particular protein or group of proteins, typically in a well-defined ...

Cornell researchers have found that a new DNA sequencing technology can be used to study how transposons move within and bind ...

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in ...

Arrowhead Pharmaceuticals (ARWR) has just gained FDA approval for REDEMPLO, its first-ever approved drug and the first siRNA therapy available for familial chylomicronemia syndrome. This regulatory ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...

The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...

Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.

Background Eosinophilic oesophagitis (EoE) is a chronic allergic disease characterised by oesophageal epithelial remodelling, barrier dysfunction and inflammation. The transcription factor forkhead ...

The agency considered clinical trial data showing Redemplo can significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome versus placebo.